Research programme: gene therapies for CNS disorders - Voyager Therapeutics

Drug Profile

Research programme: gene therapies for CNS disorders - Voyager Therapeutics

Alternative Names: AAV Frataxin; AAV-delivered gene therapies for CNS disorders - Voyager Therapeutics; AAVrh.10-vectored PHF1; ALS SOD1; Amyotrophic lateral sclerosis gene therapy - Voyager Therapeutics; Anti-Tau Antibody; Friedreich’s ataxia gene therapy - Voyager Therapeutics; Huntington's disease gene therapy - Voyager Therapeutics; VY FXN01; VY HTT01; VY SMN101; VY SOD101; VY-NAV01; VY-TAU01

Latest Information Update: 25 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Voyager Therapeutics
  • Class Analgesics; Antidementias; Gene therapies; Monoclonal antibodies; Neuroprotectants
  • Mechanism of Action Gene transference; Nav1.7-voltage-gated-sodium-channel-inhibitors; Tau protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Alzheimer's disease; Amyotrophic lateral sclerosis; Dementia; Friedreich's ataxia; Huntington's disease; Pain; Spinal muscular atrophy

Most Recent Events

  • 18 May 2018 Pharmacodynamics and adverse events data from a preclinical trial in Friedreich's ataxia released by Voyager Therapeutics
  • 17 May 2018 Pharmacodynamics and safety data from preclinical studies in Amyotrophic lateral sclerosis, and Huntington's disease released by Voyager Therapeutics
  • 10 May 2018 Voyager Therapeutics plans clinical development in Amyotrophic lateral sclerosis, Huntington's disease and Friedreich's ataxia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top